HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

IBO

Impact BioMedical Inc. (AMEX)

Healthcare — Biotechnology

Impact BioMedical Inc. discovers, develops, and commercializes products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States. The company provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application in oncology, inflammatory disorders, and neurology; and Laetose technology that is derived from a unique combination of sugar and inositol, which can inhibit the inflammatory and metabolic response of sugar alone. It also develops functional fragrance formulation, a suite of functional fragrances containing specialized botanical ingredients with application as an antimicrobial, and as an additive in insect repellents, detergents, lotions, shampoo, fabrics, and other substances. In addition, the company develops Equivir/Equivir G technology, a novel blend of polyphenols, which have demonstrated antiviral effects for use as health supplements and medications. Further, it is developing 3F (functional fragrance formulation), a formulation of botanical ingredients. Impact BioMedical Inc. was incorporated in 2018 and is based in Houston, Texas. Impact BioMedical Inc. operates as a subsidiary of DSS BioHealth Security, Inc

None
$0.48
+$0.02 (+5.22%)
Sign in to add IBO to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$52.19M
P/E Ratio (TTM)-
Forward P/E-
EPS (TTM)$-0.29
Dividend Yield-
Profit Margin-
Revenue Growth-
ROE-119.66%
Debt/Equity-
Recommendation None
Analyst Target-
Analysts-
Indexes AMEX

Technical Indicators

RSI (14)38.8
Beta-
SMA 20-
SMA 40-
52-Week High$0.83
52-Week Low$0.37
50-Day Avg$0.57
200-Day Avg$0.55
Avg Volume87.3K
Volume170.9K

Performance Analysis

NEUTRAL

IBO presents a mixed picture with both positive and negative indicators.

~ Trading at 25% of its 52-week range.
~ RSI at 38.8 is in neutral territory.
- Price is below both the 50-day and 200-day moving averages — in a downtrend.
~ Wall Street consensus is "none".

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:14 UTC

Back to Screener Export Report